References
- ScheithauerWEsophageal cancer: chemotherapy as palliative therapyAnn Oncol200415Suppl 4iv9710015477344
- BeheraMOwonikokoTKKimSConcurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic reviewOral Oncol201450988889425060589
- TakahariDSecond-line chemotherapy for patients with advanced gastric cancerGastric Cancer201720339540628260227
- HidaTNokiharaHKondoMAlectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialLancet201739010089293928501140
- KangYKBokuNSatohTNivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet2017390101112461247128993052
- KiyotaNHasegawaYTakahashiSA randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141Oral Oncol20177313814628939066
- SolomonBJMokTKimDWFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
- ArnoldDFuchsCSTaberneroJMeta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumabAnn Oncol201728122932294228950290
- AndoTHosokawaAKajiuraSEfficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapyGastric Cancer201215442743222252156
- ImaiHKomineKTakahashiSEfficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell CarcinomaChemotherapy201661526226827043795
- YonemoriKKatsumataNUnoHEfficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancerBreast Cancer Res Treat200589323724115754121
- MarkmanMZanottiKWebsterKPetersonGKulpBBelinsonJPhase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneumGynecol Oncol200391357357614675679
- TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
- TobinaiKKohnoAShimadaYToxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology GroupJpn J Clin Oncol19932342502578411739
- NoguchiSPredictive factors for response to docetaxel in human breast cancersCancer Sci200697981382016805818
- KamathKWilsonLCabralFJordanMABetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instabilityJ Biol Chem200528013129021290715695826
- MitsuhashiJTsukaharaSSuzukiRRetroviral integration site analysis and the fate of transduced clones in an MDR1 gene therapy protocol targeting metastatic breast cancerHum Gene Ther2007181089590617907967
- RestelliUCeresoliGLCroceDEconomic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness studyCancer Manag Res2017978980029263702
- de BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992